Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market Size, Value And Growth Trajectory Through 2030
The market size for the point of care (POC) tuberculosis (TB) ultra-sensitive nucleic acid amplification test (NAAT) has seen rapid expansion recently. It is projected to increase from $0.88 billion in 2025 to $1 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 13.3%. This historical growth can be attributed to several factors, including the rising prevalence of tuberculosis, the adoption of conventional molecular diagnostics, increasing government health initiatives, the expansion of hospital networks, and a growing awareness of the benefits of early diagnosis.
The point of care (POC) tuberculosis (TB) ultra-sensitive nucleic acid amplification test (NAAT) market is projected for swift expansion in the coming years. By 2030, its valuation is anticipated to reach $1.66 billion, exhibiting a compound annual growth rate (CAGR) of 13.5%. This growth during the forecast period is propelled by factors such as the rising demand for ultra-sensitive point-of-care testing, the incorporation of AI into diagnostic assays, the expansion of decentralized healthcare services, increased investment in swift nucleic acid amplification technologies, and greater funding for tuberculosis control initiatives. Key developments expected during this period involve rapid point-of-care testing, highly sensitive nucleic acid amplification, automated diagnostic platforms, compact and portable testing devices, and seamless integration with electronic health records.
Get A Free Sample Report With In-Depth Market Insights:
Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market Demand Drivers: What’s Powering Industry Growth?
The anticipated expansion of the point of care (POC) tuberculosis (TB) ultra-sensitive nucleic acid amplification test (NAAT) market is linked to the growing occurrence of infectious diseases. These conditions are defined as illnesses arising from pathogenic microbes like bacteria, viruses, parasites, or fungi, which can transmit directly or indirectly among people. The increasing density of the global population is a key factor behind the heightened prevalence of infectious diseases, as it boosts transmission risks and facilitates disease dissemination. Point-of-care tuberculosis ultra-sensitive nucleic acid amplification testing contributes to managing the increasing burden of infectious diseases by offering swift, highly sensitive, and decentralized pathogen detection, thereby enhancing early diagnosis and improving disease control initiatives. As an illustration, the UK Health Security Agency, a government health body in the UK, reported in March 2025 that tuberculosis instances in England rose by 13% in 2024, totaling 5,480 cases, up from 4,850 cases in 2023. Consequently, the expanding incidence of infectious diseases is propelling the market for the point of care (POC) tuberculosis (TB) ultra-sensitive nucleic acid amplification test (NAAT).
Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market Segment Performance And Emerging Opportunities
The point of care (POC) tuberculosis (TB) ultra-sensitive nucleic acid amplification test (NAAT) market covered in this report is segmented –
1) By Technology: Polymerase Chain Reaction Based Nucleic Acid Amplification Testing, Isothermal Amplification, Other Technologies
2) By Product Type: Instruments, Reagents And Consumables, Software
3) By Sample Type: Sputum, Blood, Urine, Other Sample Types
4) By End User: Hospitals And Clinics, Diagnostic Laboratories, Research Institutes, Other End Users
Subsegments:
1) By Polymerase Chain Reaction Based Nucleic Acid Amplification Testing: Real Time Polymerase Chain Reaction, Digital Polymerase Chain Reaction, Multiplex Polymerase Chain Reaction, Nested Polymerase Chain Reaction
2) By Isothermal Amplification: Loop Mediated Isothermal Amplification, Recombinase Polymerase Amplification, Nucleic Acid Sequence Based Amplification, Strand Displacement Amplification
3) By Other Technologies: Transcription Mediated Amplification, Helicase Dependent Amplification, Rolling Circle Amplification, Branched DNA Amplification
Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market Innovation Trends: What Developments Are Reshaping The Industry?
Major companies in the point of care (POC) tuberculosis (TB) ultra-sensitive nucleic acid amplification test (NAAT) market are focusing on regulatory validation and international prequalification programs to improve quality assurance, accelerate global adoption, and enhance access to highly sensitive diagnostic solutions. Prequalification is a regulatory assessment that evaluates in vitro diagnostic products for compliance with international standards of quality, safety, and performance, thereby enabling procurement by global health agencies and deployment in resource-limited settings. For instance, in December 2024, the World Health Organization, a Switzerland-based intergovernmental organization, announced the first prequalification of an Xpert MTB/RIF, an ultra-tuberculosis diagnostic test, under its regulatory assessment framework. This milestone supports the expansion of reliable and rapid TB detection tools, particularly across low- and middle-income countries. Leveraging advanced nucleic acid amplification technology, cartridge-based automated systems, and rapid result turnaround capabilities, the solution facilitates decentralized testing, improves early case detection, and strengthens drug-resistance identification. It is specifically engineered for deployment in primary healthcare facilities and remote regions with limited laboratory infrastructure, thus enhancing surveillance capacity, reducing diagnostic delays, and supporting global tuberculosis control and antimicrobial resistance management initiatives.
Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market Top Companies Driving Competitive Growth
Major companies operating in the point of care (POC) tuberculosis (TB) ultra-sensitive nucleic acid amplification test (NAAT) market are (POC) tuberculosis (TB) ultra-sensitive nucleic acid amplification test (NAAT) market are F. Hoffmann-La Roche AG, Abbott Laboratories, Danaher Corporation, QIAGEN N.V., SD BIOSENSOR Inc., Eiken Chemical Co. Ltd, Oxford Nanopore Technologies Ltd, Molbio Diagnostics Limited, Sansure Biotech Inc., CapitalBio Corporation, QuantuMDx Group Limited, Tata Medical Diagnostics Limited, Ustar Biotechnologies, Mylab Discovery Solutions Private Limited, GenoScreen SAS, Co-Diagnostics Inc., Longhorn Vaccines Diagnostics LLC, Akonni Biosystems Inc., Zeesan Biotech Co. Ltd, Redcliffe labs.
View The Full Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market Report:
Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market Global Footprint: Which Region Leads The Market?
North America was the largest region in the point of care (POC) tuberculosis (TB) ultra-sensitive nucleic acid amplification test (NAAT) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the point of care (POC) tuberculosis (TB) ultra-sensitive nucleic acid amplification test (NAAT) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model